1834 Investment Advisors Co. Sells 26,812 Shares of Pfizer Inc. $PFE

1834 Investment Advisors Co. reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 8.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 278,287 shares of the biopharmaceutical company’s stock after selling 26,812 shares during the quarter. 1834 Investment Advisors Co.’s holdings in Pfizer were worth $6,929,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Brighton Jones LLC grew its position in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC raised its holdings in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares in the last quarter. United Bank raised its holdings in Pfizer by 12.4% in the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after purchasing an additional 6,415 shares in the last quarter. Sei Investments Co. lifted its position in shares of Pfizer by 31.5% in the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock worth $63,889,000 after purchasing an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC boosted its stake in shares of Pfizer by 45.3% during the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after purchasing an additional 31,896 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE opened at $27.01 on Monday. Pfizer Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $28.75. The firm’s 50-day simple moving average is $27.23 and its two-hundred day simple moving average is $26.06. The stock has a market cap of $153.56 billion, a PE ratio of 19.86 and a beta of 0.43. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business’s revenue was down 1.2% on a year-over-year basis. During the same period last year, the business earned $0.63 earnings per share. Analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. Pfizer’s payout ratio is presently 126.47%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Board declared a $0.43 Q2 dividend (payable June 12; ex-div May 8), reinforcing Pfizer’s long track record of income (350th consecutive quarterly dividend) and supporting demand from income-minded investors. Pfizer Declares Second-Quarter 2026 Dividend
• Positive Sentiment: Seagen acquisition appears to be contributing to growth and a stronger oncology franchise (Antibody‑Drug Conjugates), supporting medium-term revenue upside as Pfizer expands cancer capabilities. Pfizer Inc. (PFE): One of the Best Safe Stocks to Invest in for Beginners
• Positive Sentiment: GLP‑1 obesity program momentum — Phase 2b monthly GLP‑1 data and plans for a large clinical program provide optionality beyond legacy drugs and could open a new growth engine if later‑stage trials succeed. Pfizer’s Monthly GLP-1 Push Tests Balance Between Obesity Growth And Dividends
• Positive Sentiment: Multiple early‑stage pipeline advances (completion of a China Phase 1 for a heart‑failure candidate, new gastric‑emptying study for an obesity asset, new Phase 1 cancer and liver studies) add cadence and long‑term upside to the pipeline. Pfizer Advances Early-Stage Heart Failure Candidate With Completion Of Chinese Phase 1 Study
• Neutral Sentiment: Pfizer released results from its 2026 shareholder meeting — largely procedural items that don’t materially change near‑term fundamentals. Pfizer Unveils 2026 Shareholder Meeting Results
• Neutral Sentiment: Bristol Myers and Pfizer will make Eliquis available through Mark Cuban’s Cost Plus pharmacy starting April 27 — improves patient access but raises questions about pricing/volume tradeoffs; watch margin impact. Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban’s online pharmacy
• Neutral Sentiment: Broader industry news — competitors (e.g., Eli Lilly, Novo Nordisk) continue to shape the obesity/GLP‑1 landscape; this is both competitive risk and market validation for Pfizer’s obesity push. Eli Lilly’s new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims
• Negative Sentiment: Pfizer ended a Phase 1 cancer trial, trimming part of its oncology pipeline — a reminder that not all program investments convert to later‑stage value and a near‑term negative headline. Pfizer Ends Early-Stage Cancer Trial, Trimming Its Oncology Pipeline
• Negative Sentiment: Analyst skepticism persists (Barclays remains negative; consensus leans to “hold”), which can cap upside until clearer revenue/cost trajectories emerge. Barclays Remains a Sell on Pfizer (PFE)

Analyst Ratings Changes

Several equities analysts recently issued reports on PFE shares. TD Cowen reissued a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, February 4th. Morgan Stanley lifted their price objective on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Guggenheim increased their target price on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Finally, Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a research note on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $28.48.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.